REG - Allergy Therapeutics - Result of AGM

Allergy TherapeuticsAnnouncement

08/03/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240308:nRSH2043Ga&default-theme=true

RNS Number : 2043G  Allergy Therapeutics PLC  08 March 2024

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

8 March 2024 Allergy Therapeutics plc (AIM:AGY), the fully integrated
specialty pharmaceutical group specialising in allergy vaccines, announces
that all resolutions proposed at the 2023 Annual General Meeting ("AGM") held
today were duly passed by shareholders by way of poll vote.

 

Resolutions 1 to 11 (inclusive) were proposed as ordinary resolutions and
resolutions 12 to 14 (inclusive) were proposed as special resolutions. The
results of the proxy votes received ahead of the meeting are outlined in the
table below.

 

 Resolution                                                                    For:           %age     Against:    %age   Total Votes Cast  Withheld
 1. Approval of 2023 Accounts                                                  4,454,427,655  100.00%  100,000     0.00%  4,454,529,660     2,005
 2. Approval of Directors'                                                     4,440,353,568  99.68%   14,174,087  0.32%  4,454,529,660     2,005

 Remuneration Report
 3. To re-elect Mary Tavener as a Director                                     4,454,239,121  99.99%   278,279     0.01%  4,454,529,660     12,260
 4. To re-elect Tunde Otulana as a Director                                    4,454,384,117  100.00%  133,283     0.00%  4,454,529,660     12,260
 5. To re-elect Manuel Llobet as a Director                                    4,454,284,117  99.99%   233,283     0.01%  4,454,529,660     12,260
 6. To re-elect Cheryl MacDiarmid as a Director                                4,454,384,117  100.00%  133,283     0.00%  4,454,529,660     12,260
 7. To re-elect Peter Jensen O.B.E. as a Director                              4,440,494,882  99.69%   14,015,154  0.31%  4,454,529,660     19,624
 8. To re-appoint BDO LLP as auditors of the Company                           4,454,306,655  100.00%  221,000     0.00%  4,454,529,660     2,005
 9. To authorise the Directors to agree the Auditors remuneration              4,454,415,654  100.00%  108,001     0.00%  4,454,529,660     6,005
 10. To authorise the Directors to allot the unissued share capital up to a    4,454,236,175  99.99%   291,480     0.01%  4,454,529,660     2,005
 specific amount (s.551)
 11. Authority to issue warrants                                               4,440,359,504  99.68%   14,168,151  0.32%  4,454,529,660     2,005
 12. Special Resolution:  To authorise the Directors to allot equity           4,440,458,304  99.68%   14,069,351  0.32%  4,454,529,660     2,005
 securities for cash without first being required to offer such shares to
 existing shareholders for a period expiring at the conclusion of the next
 annual general meeting of the Company or 31 December 2024, whichever occurs
 first.
 13. Special Resolution: To authorise the Directors to allot equity            4,440,458,304  99.68%   14,069,351  0.32%  4,454,529,660     2,005

 securities and/or sell treasury shares for cash without first

 being required to offer such securities to existing shareholders
 14. Special Resolution: Disapplication of pre-emption                         4,440,428,445  99.68%   14,095,210  0.32%  4,454,529,660     6,005

 rights in relation to the Warrants

 

 

 

- ENDS -

 

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSSWFDAELSELD